Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria

NCT03847909 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03847909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03847909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
October 28, 2019
Completion date
June 29, 2021
Enrollment
35 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

genetic disease, kidney diseases, primary hyperoxaluria type 1 (ph1), primary hyperoxaluria type 2 (ph2), urologic diseases